Goldman Sachs Group Inc Krystal Biotech, Inc. Transaction History

Goldman Sachs Group Inc

  • $605 Billion
  • Q3 2024

A detailed history of Goldman Sachs Group Inc transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 301,354 shares of KRYS stock, worth $53.7 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
301,354
Previous 422,331 28.65%
Holding current value
$53.7 Million
Previous $77.6 Million 29.34%
% of portfolio
0.01%
Previous 0.01%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
SELL
$174.7 - $213.66 $21.1 Million - $25.8 Million
-120,977 Reduced 28.65%
301,354 $54.8 Million
Q2 2024

Aug 13, 2024
SELL
$153.12 - $183.64 $1.87 Million - $2.25 Million
-12,243 Reduced 2.82%
422,331 $77.6 Million
Q1 2024

May 15, 2024
BUY
$108.01 - $179.35 $22.3 Million - $37 Million
206,521 Added 90.56%
434,574 $77.3 Million
Q4 2023

Feb 13, 2024
BUY
$96.0 - $128.29 $4.2 Million - $5.61 Million
43,709 Added 23.71%
228,053 $28.3 Million
Q3 2023

May 14, 2024
SELL
$108.51 - $130.22 $4.74 Million - $5.69 Million
-43,709 Reduced 19.17%
184,344 $21.4 Million
Q3 2023

Nov 14, 2023
SELL
$108.51 - $130.22 $1.15 Million - $1.38 Million
-10,592 Reduced 5.43%
184,344 $21.4 Million
Q2 2023

May 14, 2024
SELL
$78.48 - $130.32 $4.94 Million - $8.2 Million
-62,924 Reduced 24.4%
194,936 $22.9 Million
Q2 2023

Aug 14, 2023
SELL
$78.48 - $130.32 $4.94 Million - $8.2 Million
-62,924 Reduced 24.4%
194,936 $22.9 Million
Q1 2023

May 14, 2024
BUY
$72.39 - $84.27 $7.98 Million - $9.29 Million
110,259 Added 74.7%
257,860 $20.6 Million
Q1 2023

May 11, 2023
BUY
$72.39 - $84.27 $7.98 Million - $9.29 Million
110,259 Added 74.7%
257,860 $20.6 Million
Q4 2022

May 14, 2024
BUY
$63.14 - $79.9 $329,338 - $416,758
5,216 Added 3.66%
147,601 $11.7 Million
Q4 2022

Feb 13, 2023
BUY
$63.14 - $79.9 $329,338 - $416,758
5,216 Added 3.66%
147,601 $11.7 Million
Q3 2022

May 14, 2024
SELL
$64.85 - $82.4 $1.39 Million - $1.76 Million
-21,359 Reduced 13.04%
142,385 $9.92 Million
Q3 2022

Nov 10, 2022
SELL
$64.85 - $82.4 $1.39 Million - $1.76 Million
-21,359 Reduced 13.04%
142,385 $9.92 Million
Q2 2022

May 14, 2024
SELL
$48.93 - $73.47 $3.15 Million - $4.72 Million
-64,309 Reduced 28.2%
163,744 $10.8 Million
Q2 2022

Aug 15, 2022
BUY
$48.93 - $73.47 $1.36 Million - $2.03 Million
27,697 Added 20.36%
163,744 $10.8 Million
Q1 2022

May 16, 2022
BUY
$51.99 - $72.11 $4.31 Million - $5.98 Million
82,894 Added 155.95%
136,047 $9.05 Million
Q4 2021

Feb 14, 2022
BUY
$39.81 - $88.24 $1.27 Million - $2.81 Million
31,828 Added 149.25%
53,153 $3.72 Million
Q3 2021

Nov 10, 2021
BUY
$52.01 - $71.77 $1.11 Million - $1.53 Million
21,325 New
21,325 $1.11 Million

Others Institutions Holding KRYS

# of Institutions
310
Shares Held
24.4M
Call Options Held
483K
Put Options Held
364K
View Full List

About Krystal Biotech, Inc.

KRYS Quotes by TradingView
  • Ticker KRYS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,664,300
  • Market Cap $4.57B
  • Description
  • Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...
More about KRYS
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email